Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group companion study, EST 4189

被引:116
作者
Simpson, JF
Gray, R
Dressler, LG
Cobau, CD
Falkson, CI
Gilchrist, KW
Pandya, KJ
Page, DL
Robert, NJ
机构
[1] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ N Carolina, Chapel Hill, NC USA
[4] Flower Mem Hosp, Sylvania, OH USA
[5] Univ Pretoria, ZA-0002 Pretoria, South Africa
[6] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[7] Univ Rochester, Ctr Canc, Rochester, NY USA
[8] Fairfax Hosp, Falls Church, VA 22046 USA
关键词
D O I
10.1200/JCO.2000.18.10.2059
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The identification of a subset of patients with axillary lymph node-positive breast cancer with an improved prognosis would be clinically useful. We report the prognostic importance of histologic grading and proliferative activity in a cohort of patients with axillary lymph node-positive breast cancer and compare these parameters with other established prognostic factors. Patients and Methods: This Eastern Cooperative Oncology Group laboratory companion study (E4189) centered on 560 axillary lymph node-positive patients registered onto one of six eligible clinical protocols. Flow cytometric (ploidy and S-phase fraction [SPF]) and histopathologic analyses (Nottingham Combined Histologic Grade and mitotic index) were performed on paraffin-embedded tissue from 368 patients. Results: Disease recurred in 208 patients; in 161 (77%), within the first 5 years. Mitotic index and grade were associated with both ploidy and SPF (P less than or equal to.01). Within the first 5 years of follow-up, mitotic index (P =.004), grade (P =.004), ploidy (P =.006), and SPF (P =.05) were associated with time to recurrence; there was also a significant association with survival. The effect of mitotic index was largely a result of the difference between 0 to 2 mitoses/10 high-power fields (HPF; 5-year recurrence of 31%) and more than 2 mitoses/10 HPF (5-year recurrence of 52%). The 0 to 2 mitoses/10 HPF group was independently associated with improved prognosis at 5 years (P =.002) in regression models that included other standard prognostic factors. Conclusion: A subset of axillary lymph node-positive patients with improved prognosis may be identified using a lower (< 3 mitoses/10 HPF) mitotic count than is usually performed. J Clin Oncol 18:2059-2069. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:2059 / 2069
页数:11
相关论文
共 51 条
[31]   PROLIFERATION MARKERS IN BREAST-CARCINOMA - MITOTIC FIGURE COUNT, S-PHASE FRACTION, PROLIFERATING CELL NUCLEAR ANTIGEN, KI-67 AND MIB-1 [J].
KESHGEGIAN, AA ;
CNAAN, A .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1995, 104 (01) :42-49
[32]   Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi [J].
MacGrogan, G ;
Mauriac, L ;
Durand, M ;
Bonichon, F ;
Trojani, M ;
deMascarel, I ;
Coindre, JM .
BRITISH JOURNAL OF CANCER, 1996, 74 (09) :1458-1465
[33]   PREDICTION OF PROGNOSIS IN AXILLARY LYMPH-NODE POSITIVE BREAST-CANCER PATIENTS - A STATISTICAL STUDY [J].
MAEHLE, BO ;
SKJAERVEN, R .
BRITISH JOURNAL OF SURGERY, 1984, 71 (06) :459-462
[34]  
MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
[35]  
MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756
[36]   C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER [J].
MUSS, HB ;
THOR, AD ;
BERRY, DA ;
KUTE, T ;
LIU, ET ;
KOERNER, F ;
CIRRINCIONE, CT ;
BUDMAN, DR ;
WOOD, WC ;
BARCOS, M ;
HENDERSON, IC .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (18) :1260-1266
[37]   NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC SUBGROUPS DEFINED BY TUMOR SIZE AND FLOW-CYTOMETRY [J].
OREILLY, SM ;
CAMPLEJOHN, RS ;
BARNES, DM ;
MILLIS, RR ;
RUBENS, RD ;
RICHARDS, MA .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (12) :2040-2046
[38]  
PAGE DL, 1995, AM J CLIN PATHOL, V103, P123
[39]  
PAGE DL, 1987, DIAGNOSTIC HISTOPATH, P193
[40]  
PARL FF, 1982, CANCER, V50, P2410, DOI 10.1002/1097-0142(19821201)50:11<2410::AID-CNCR2820501128>3.0.CO